Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100

Benzinga · 2d ago
Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $85 to $100.